DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Sun Pharmaceutical Industries Limited (SUNPHARMA) share price today?

Sun Pharmaceutical Industries Limited (SUNPHARMA) is trading at ₹1,758.8 on the NSE, down 0.29% on the day. Source: DocStoX.

What is the PE ratio of Sun Pharmaceutical Industries Limited?

Sun Pharmaceutical Industries Limited has a price-to-earnings (PE) ratio of 36.8 in the Healthcare sector.

What is the market capitalisation of Sun Pharmaceutical Industries Limited?

Sun Pharmaceutical Industries Limited has a market capitalisation of approximately ₹4.22 lakh crore.

Is Sun Pharmaceutical Industries Limited a profitable company?

Sun Pharmaceutical Industries Limited generates a return on equity of 13.7% with a net profit margin of 19.7%. That is a reasonable return on shareholder capital.

What is the 52-week high and low of SUNPHARMA?

Sun Pharmaceutical Industries Limited (SUNPHARMA) has traded between ₹1,583.7 and ₹2,046.9 over the past 52 weeks, against a current price of ₹1,758.8.

Does Sun Pharmaceutical Industries Limited pay a dividend?

Yes. Sun Pharmaceutical Industries Limited currently offers a dividend yield of 0.86%. Dividend payments depend on the board's declaration each year.

Sun Pharmaceutical Industries Limited

F&O

₹1,758.80▼ -5.20 (-0.29%)

SUNPHARMA·NSE·Healthcare

Market Cap

422273.01 Cr

PE Ratio

36.79

Volume

15,22,442

Day High - Low

1764.90 - 1743.50

52W High-Low

2046.90 - 1583.70

₹1,758.80▼ -5.20 (-0.29%)

Market Cap422273.01 Cr

PE Ratio36.79

Volume15,22,442

Day High - Low1764.90 - 1743.50

52W High-Low2046.90 - 1583.70

Sun Pharmaceutical Industries Limited (SUNPHARMA): company summary

The company's annual revenue rose 11.2% to ₹58,462 crore, while annual net profit increased 5.0% to ₹11,509 crore.

Sun Pharmaceutical Industries Limited (SUNPHARMA) is a large-cap Healthcare company valued at ₹4.22 lakh crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: Sun Pharmaceutical Industries Limited last traded at ₹1,758.8, modestly down 0.29% on the day.
Recent developments: On 2026-10-07, the company's board will consider a ₹15,000 crore NCD issue. On 2026-08-04, the company was noted to be positioned to benefit from patent expiry of blockbuster medicines, creating growth opportunities.
Financial performance: The company's annual revenue rose 11.2% to ₹58,462 crore, while annual net profit increased 5.0% to ₹11,509 crore. The latest quarter saw revenue rise 10.5% to ₹15,300 crore and net profit jump 26.5% to ₹2,901 crore, outpacing the same quarter a year earlier.
Valuation multiples: The stock trades at 36.8 times earnings, broadly in line with the Healthcare median of 32.0, 5.35 times book value. It yields 0.9%.
Things to watch: The net profit margin narrowed 1.2 percentage points to 19.7%. Promoter holding fell 1.80 percentage points to 52.68%. The stock is 14.1% below its 52-week high.
Where it stands: The company's revenue and net profit grew year-on-year, with the latest quarter showing strong gains. The net profit margin declined, and promoter holding decreased, while the stock is below its 52-week high.

Summarised by DocStoX's model on 2026-10-17 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

6.1/10

Fair

Fair Value

ROE

13.74%

Average

P/E

36.79x

Expensive

Debt / Equity

0.06

Low

Industry

Healthcare

Pharmaceuticals

Overall View

Mixed

Price performance

NIFTY 50NIFTY 100NIFTY 200

Day₹1744

₹1765

52W₹1584

₹2047

DocStoX take

Supported by risk (9.6) and growth (8.4), but held back by valuation (1.2). Risk looks strong at 9.6, but that is offset by valuation at 1.2. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence

6.1

/10

Fair

Quality

Solid

ROE 13.7%

Valuation

Expensive

P/E 36.8×

Growth

Strong

Revenue +11.8% 5Y CAGR

Risk

Low risk

D/E 0.06

Momentum

Soft

38% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹1,759

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹4.22L Cr

52W High / Low

₹2047 / ₹1584

Dividend Yield

0.86%

Promoter Holding

52.68%

EPS (TTM)

₹47.80

Book Value

₹348.31

Key highlights

Profit compounding 38% a year
Low leverage — D/E 0.06
Profitable in all of the last 5 years
Valuation is weak (1.2/10)

4 Positives1 Watchout

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore Sun Pharmaceutical Industries Limited’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

Sun Pharmaceutical Industries Limited peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Divi's Laboratories Limited Torrent Pharmaceuticals Limited Apollo Hospitals Enterprise Limited Zydus Lifesciences Limited Laurus Labs Limited Cipla Limited Dr. Reddy's Laboratories Limited Aurobindo Pharma Limited Mankind Pharma Limited Lupin Limited Manipal Health Enterprises Limited Max Healthcare Institute Limited

Compare Sun Pharmaceutical Industries Limited with peers

Sun Pharmaceutical Industries Limited vs Divi's Laboratories Limited Sun Pharmaceutical Industries Limited vs Torrent Pharmaceuticals Limited Sun Pharmaceutical Industries Limited vs Apollo Hospitals Enterprise Limited Sun Pharmaceutical Industries Limited vs Zydus Lifesciences Limited Sun Pharmaceutical Industries Limited vs Laurus Labs Limited Sun Pharmaceutical Industries Limited vs Cipla Limited

Related tools & concepts

Value Sun Pharmaceutical Industries Limited with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

SUNPHARMA newsLatest coverage & filings Open screenerFilter the whole market